Recombinant Human Erythropoietin Augments Neovascularization Responses in a Neonatal Rat Model of Premature Brain Damage by Phosphatidylinositol 3 Kinase/Akt Pathway
Background: Recombinant human-erythropoietin (rh-EPO) has therapeutic efficacy for premature infants with brain damage during the active rehabilitation and anti-inflammation. In the present study, we found that the rh-EPO was related to the promotion of neovascularization. Our aim was to investigat...
Main Authors: | Da-Fan Yu, Li-Hua Zhu, Li Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2017-01-01
|
Series: | Chinese Medical Journal |
Subjects: | |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2017;volume=130;issue=7;spage=854;epage=858;aulast=Yu |
Similar Items
-
Expression of hypoxia-inducible factor-1α and erythropoietin at corneal neovascularization in rats
by: Ji-Min Wang, et al.
Published: (2014-12-01) -
Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research
by: Dorothy E. Oorschot, et al.
Published: (2020-02-01) -
Inhibition of erythropoietin siRNA on corneal neovascularization of rabbit
by: Yu-Shun Xue, et al.
Published: (2017-03-01) -
Therapeutic effect of erythropoietin on brain injury in premature mice with intrauterine infection
by: Hongxue Liu, et al.
Published: (2020-08-01) -
Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants
by: Huiqing Sun, et al.
Published: (2020-10-01)